Cat FIP Treatment Access and Welfare

Feline infectious peritonitis has transformed from a uniformly fatal disease to one with a high cure rate through antiviral drug treatment, dramatically improving welfare outcomes for affected cats.

Key Facts

FIP is caused by virulent mutations of feline enteric coronavirus and was previously uniformly fatal
Nucleoside analogue antivirals including GS-441524 achieve remission in the majority of treated cats
Treatment requires 12 weeks of daily oral or injectable medication with regular monitoring
Access to licensed antivirals remains problematic in some countries, driving use of unlicensed compounds
Both wet and dry forms of FIP, including neurological disease, respond to antiviral treatment
Relapse can occur after treatment completion and requires additional treatment courses

Welfare Considerations

The development of effective antiviral treatment for FIP represents one of the most dramatic welfare advances in feline medicine in recent decades. Cats with FIP previously faced certain death within weeks to months from a painful, progressive disease. Treated cats now commonly achieve full clinical remission and extended disease-free survival. The welfare implications of treatment access inequity are significant: cats in countries without licensed drug access face avoidable suffering and death from a now-treatable condition. Advocacy for improved drug access and affordability is both a welfare and equity issue.

What You Can Do

Seek specialist feline internal medicine assessment immediately if FIP is suspected in your cat
Discuss treatment options including licensed and unlicensed antiviral access with your vet
Support veterinary campaigns for improved access to licensed FIP antivirals globally
Monitor treated cats carefully for relapse and report any return of clinical signs to your vet
Donate to feline disease research organisations working on improved FIP treatment protocols